Shana Kelley, CTRL Therapeutics founder and chief technology officer
A new cell therapy biotech emerges to find solid tumor-killing immune cells in patients' blood
A new autologous cell therapy maker is coming to the fore with $10 million to start.
Chicago-based CTRL Therapeutics hopes to expand beyond the current …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
